. Author manuscript; available in PMC: 2022 Oct 30.

Published in final edited form as: Radiology. 2017 Oct 16;286(1):326–337. doi: 10.1148/radiol.2017162899

Table 1.

Patient Characteristics (n=26)^*

Age	82 (SD 10) y; (range 56–94 y)
Gender (female)	8
Pre MRI eGFR (mL/min/1.73m²)	32 (SD 11)
Pre MRI creatinine	2.0 (SD 0.8) mg/dL
CKD Stage 5	n=2 (8%)
CKD Stage 4	n=10 (38%)
CKD Stage 3b	n=11 (42%)
CKD Stage 3a	n=3 (12%)
CKD Stage 1–2	n=0 (0%)
Post-TAVR creatinine^*	1.9 (SD 0.8) mg/dL
Post-TAVR eGFR^* (mL/min/1.73m²)	36 (SD 13)
Hemoglobin	11 (SD 2) g/dL
Weight	80 (SD 16) kg
Total iodinated contrast (n=19)^**	95 (SD 39) mL
Total fluoroscopy time (radiation dose) (n=19)	14 (SD 7) minutes 1643 (SD 1125) mGy
Time in cath lab (n=19)	100 (SD 30) minutes

Nineteen patients proceeded to TAVR.

^**

Typical institutional range of total contrast for TAVR is 133 (SD 69) mL, p=0.02.

CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate